Iron Overload: Consequences, Assessment, and Monitoring

REFERENCES

• Anderson GJ. Mechanisms of iron loading and toxicity. Am J Hematol. 2007;82(Suppl.):1128–1131.
   PubMed Web of Science ®Google Scholar
• Harmatz P, Butensky E, Quirolo K, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood. 2000;96:76–79.
   PubMed Web of Science ®Google Scholar
• Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in b-thalassemia. Haematologica. 2007;92:583–588.
   PubMed Web of Science ®Google Scholar
• Kearney SL, Nemeth E, Neufeld EJ, et al. Urinary hepcidin in congenital chronic anemias. Pediatr Blood Cancer. 2007;48:57–63.
   PubMed Web of Science ®Google Scholar
• Hershko C, Graham G, Bates GW, Rachmilewitz EA. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol. 1978;40:255–263.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Tavazzi D, Duca L, Marelli S, Fiorelli G. Non-transferrin-bound iron, iron-related oxidative stress and lipid peroxidation in β-thalassemia intermedia. Transfus Sci. 2000;23:245–246.
   PubMedGoogle Scholar
• Cighetti G, Duca L, Bortone L, et al. Oxidative status and malondialdehyde in β-thalassaemia patients. Eur J Clin Invest. 2002;32(Suppl. 1):55–60.
   PubMed Web of Science ®Google Scholar
• Taher A. Iron overload in thalassemia and sickle cell disease. Semin Hematol. 2005;42(2 Suppl. 1): S5–S9.
   Google Scholar
• Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann N Y Acad Sci. 1998; 850:191–201.
   PubMed Web of Science ®Google Scholar
• Conte D, Piperno A, Mandelli C, et al. Clinical, biochemical and histological features of primary haemochromatosis: a report of 67 cases. Liver. 1986;6:310–315.
   Google Scholar
• Thakerngpol K, Fucharoen S, Boonyaphipat P, et al. Liver injury due to iron overload in thalassemia: histopathologic and ultrastructural studies. Biometals. 1996;9:177–183.
   PubMed Web of Science ®Google Scholar
• Olivieri NF. Progression of iron overload in sickle cell disease. Semin Hematol. 2001;38:57–62.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331:574–578.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci. 1998;850:227–231.
   PubMed Web of Science ®Google Scholar
• Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E. Thalassemia. Hematology Am Soc Hematol Educ Program. 2004;14–34.
   PubMedGoogle Scholar
• Wood JC. Cardiac iron across different transfusion-dependent diseases. Blood Rev. 2008;22: S14–S21.
   PubMed Web of Science ®Google Scholar
• Shalitin S, Carmi D, Weintrob N, et al. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. Eur J Haematol. 2005;74:93–100.
   PubMed Web of Science ®Google Scholar
• Gabutti V, Piga A. Results of longterm iron-chelating therapy. Acta Haematol. 1996;95:26–36.
   PubMed Web of Science ®Google Scholar
• Telfer PT, Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol. 2000;110:971–977.
   PubMed Web of Science ®Google Scholar
• Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood. 2004;104:263–269.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187–1193.
   PubMed Web of Science ®Google Scholar
• Taher A, El RF, Isma'eel H, Koussa S, Inati A, Cappellini MD. Correlation of liver iron concentration determined by R2 MRI with serum ferritin in patients with thalassemia intermedia. Haematologica. 2008;93:1584–1585.
   PubMed Web of Science ®Google Scholar
• Pakbaz Z, Fischer R, Fung E, Nielsen P, Harmatz P, Vichinsky E. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer. 2007;49:329–332.
   PubMed Web of Science ®Google Scholar
• Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassaemia major. N Engl J Med. 2000;343:327–331.
   PubMed Web of Science ®Google Scholar
• Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassaemia major. N Engl J Med. 1994;331:567–573.
   PubMed Web of Science ®Google Scholar
• Angelucci E, Baronciani D, Lucarelli G, et al. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. Br J Haematol. 1995;89:757–761.
   PubMed Web of Science ®Google Scholar
• Jensen PD, Jensen FT, Christensen T, Nielsen JL, Ellegaard J. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood. 2003;101:91–96.
   PubMed Web of Science ®Google Scholar
• Villeneuve JP, Bilodeau M, Lepage R, Cote J, Lefebvre M. Variability in hepatic iron concentration measurement from needle- biopsy specimens. J Hepatol. 1996;25:172–177.
   PubMed Web of Science ®Google Scholar
• St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105:855–861.
   PubMed Web of Science ®Google Scholar
• Voskaridou E, Douskou M, Terpos E, et al. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. Br J Haematol. 2004;126:736–742.
   PubMed Web of Science ®Google Scholar
• Brittenham GM, Cohen AR, McLaren CE, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol. 1993;42:81–85.
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171–2179.
   PubMed Web of Science ®Google Scholar
• Westwood MA, Anderson LJ, Maceira AM, et al. Normalized left ventricular volume and function in thalassaemia major patients with normal myocardial iron. J Magn Reson Imaging. 2007;25:1147–1151.
   PubMed Web of Science ®Google Scholar
• Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2004;103:1934–1936.
   PubMed Web of Science ®Google Scholar
• Raman SV, Simonetti OP, Cataland SR, Kraut EH. Myocardial ischemia and right ventricular dysfunction in adult patients with sickle cell disease. Haematologica. 2006;91:1329–1335.
   Google Scholar
• Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood. 2003; 101:4632–4639.
   PubMed Web of Science ®Google Scholar
• Breuer W, Hershko C, Cabantchik ZI. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci. 2000;23:185–192.
   PubMedGoogle Scholar
• Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005;18:277–287.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A. Guidelines for the Clinical Management of Thalassaemia. 2nd revised ed. Nicosia, Cyprus: Thalassaemia International Federation; 2008.
   Google Scholar
• Taher A, Isma'eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis. 2006; 37:12–20.
   PubMed Web of Science ®Google Scholar
• Aessopos A, Kati M, Farmakis D. Heart disease in thalassemia intermedia: a review of the underlying pathophysiology. Haematologica. 2007;92:658–665.
   PubMed Web of Science ®Google Scholar
• Aessopos A, Kati M, Meletis J. Thalassemia intermedia today: should patients regularly receive transfusions?. Transfusion 2007;47:792–800.
   PubMed Web of Science ®Google Scholar